Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses

The discovery of new adjuvants that can stimulate the immune response to protein antigens is a major issue for the development of subunit vaccines. Lipoprotein oxidation occurring during the acute phase response (APR) to aggression of the organism, provides signals of danger that are detected by den...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 24; no. 9; pp. 1254 - 1263
Main Authors Perrin-Cocon, Laure, Agaugué, Sophie, Coutant, Frédéric, Saint-Mézard, Pierre, Guironnet-Paquet, Aurélie, Nicolas, Jean-François, André, Patrice, Lotteau, Vincent
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 27.02.2006
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The discovery of new adjuvants that can stimulate the immune response to protein antigens is a major issue for the development of subunit vaccines. Lipoprotein oxidation occurring during the acute phase response (APR) to aggression of the organism, provides signals of danger that are detected by dendritic cells (DC). Among other instructive molecules generated during the APR, lysophosphatidylcholine (LPC) promotes mature DC generation from differentiating human monocytes in vitro. It is shown here that LPC also controls the initiation of an adaptive immune response in vivo. LPC displays adjuvant properties when injected to mice in mixture with various antigens. Immunizations with LPC induced the production of antigen-specific antibodies with an efficiency similar to Alum, the reference adjuvant for human vaccination. Importantly, LPC also induced cytotoxic T cell responses, opening perspectives for vaccine development. Therefore, LPC is a natural adjuvant for the immune system, inducing humoral and cellular immune responses.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0264-410X
1873-2518
0264-410X
DOI:10.1016/j.vaccine.2005.09.036